Clinical Trials Logo

Herpes Zoster clinical trials

View clinical trials related to Herpes Zoster.

Filter by:

NCT ID: NCT01137669 Completed - Herpes Zoster Clinical Trials

ZOSTAVAX® in Renal Transplant Patients

Start date: September 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of a licensed zoster vaccine, ZOSTAVAX® (Zoster Vaccine Live) in 40 subjects, age 18 years or older, with chronic kidney disease (CKD) who are scheduled to receive a living donor kidney transplant. ZOSTAVAX® is not licensed for use in immunosuppressed persons and in the United States for individuals less than 50 years of age. Subjects will receive either ZOSTAVAX® vaccine or placebo (inactive substance) no less than 4 weeks prior to their kidney transplant. Study procedures include: physical exam, blood samples and documentation of daily temperatures and/or side effects in a diary following vaccination. Participants may be involved in study related procedures for up to 18 months.

NCT ID: NCT01132729 Completed - Herpes Zoster Clinical Trials

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions

Start date: September 2006
Phase: N/A
Study type: Interventional

The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fasting conditions.

NCT ID: NCT01132716 Completed - Herpes Zoster Clinical Trials

Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

Start date: September 2006
Phase: N/A
Study type: Interventional

The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.

NCT ID: NCT01086449 Completed - Herpes Zoster Clinical Trials

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

Start date: March 4, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.

NCT ID: NCT01077804 Completed - Herpes Zoster Clinical Trials

A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)

Start date: June 1995
Phase: N/A
Study type: Observational

The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAX® [Varicella Virus Vaccine Live (Oka/Merck)] and to assess the impact of the vaccine on the epidemiology of varicella and herpes zoster.

NCT ID: NCT00986232 Completed - Measles Clinical Trials

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Start date: April 1999
Phase: Phase 2
Study type: Interventional

A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.

NCT ID: NCT00985166 Completed - Measles Clinical Trials

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Start date: August 2000
Phase: Phase 3
Study type: Interventional

The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.

NCT ID: NCT00985153 Completed - Measles Clinical Trials

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Start date: March 2000
Phase: Phase 3
Study type: Interventional

This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.

NCT ID: NCT00975507 Completed - Measles Clinical Trials

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Start date: March 1998
Phase: Phase 3
Study type: Interventional

This study will compare Measles, Mumps, Rubella, and Varicella Vaccine (V221) and concomitant administration of Varivax and M-M-R II vaccines in healthy children.

NCT ID: NCT00969436 Completed - Measles Clinical Trials

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Start date: November 9, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to the current standard of care which is Priorix™ administered at 9 months of age followed by concomitant administration of Priorix™ with Varilrix™ at 15 months of age in a measles endemic environment such as India.